Follow us on our mission to treat fibrosis and restore organ function in multiple therapeutic areas
Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
Antwerp, Belgium, November 18, 2024
Agomab Therapeutics NV (‘Agomab’) today announced the appointment of Colin Bond to the company’s Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades at leading international corporations, Colin also brings fifteen years of experience as a CFO at listed biopharmaceutical companies in Switzerland, Germany and the US
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis- focused Pipeline
Antwerp, Belgium, October 25, 2024
Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi and Invus,as well as existing investors.
The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5 (TGFβ1R), in patients with fibrostenosing Crohn’s disease (FSCD). Interim data from the Phase 2a STENOVA trial are expected in the first quarter of 2025. In addition, proceeds will be used to advance the clinical
development for AGMB-447, a lung-restricted inhaled small molecule inhibitor of ALK5, that is currently in a Phase 1 clinical trial in healthy subjects and patients with idiopathic pulmonary fibrosis (IPF), as well as initial clinical development of AGMB-101, a full MET agonistic antibody currently in the final stages of IND-enabling studies, which the company intends to develop for liver cirrhosis.
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Antwerp, Belgium, July 11, 2024
Agomab Therapeutics NV (‘Agomab’) today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (Nasdaq: CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac’s financial and capital markets activities since 2016, characterized by a successful listing on Nasdaq and two subsequent follow-on offerings. Under his leadership, CureVac raised over $1.6 billion in equity. Mr. Kemula will succeed Tolga Hassan, who has recently left the company to explore new opportunities closer to home. Following Mr. Hassan’s departure, Paul van der Horst, Agomab’s Chief Business Officer, has been acting as Chief Financial Officer.
“WE ARE DETERMINED TO IMPROVE THE LIVES OF PATIENTS WITH FIBROTIC DISEASES. WE ARE BUILDING A LEADING COMPANY THAT COMBINES TRANSFORMATIVE SCIENCE WITH THE COMMITMENT AND PASSION OF OUR EXPERIENCED TEAM, PARTNERS, AND INVESTORS.”
Tim Knotnerus, Chief Executive Officer
